Ann: Preliminary Final Report, page-5

Rhino Swab only contributed 3 M to earnings so plenty of room for growth there with limited extra expenditure required. If the Mute side can continue its trajectory then with Rhino swab staring to add value I can see CFP happening next quarter easily. I also think Rhino swab has legs beyond covid and into respiratory testing in general so does the company so its a good slow burner.

What I like most is that they havnt forgotten their core product (mute) and still see value in this alone. I still believe Rhino swab will take over this in earnings but Mute should be a great base to build this on.

Now we just need the share price to move!